From 8322 patients for whom creatine kinase (CK; EC 2.7.3.2) isoenzyme analysis was ordered, we identified 136 patients with macro CK isoenzyme in their serum. There were 36 cases with type 1 (prevalence: 0.43%) and 100 cases with type 2 isoenzyme (prevalence: 1.20%). About three-fourths of the patients were ambulatory at the time of testing, and -90% of the first 68 patients identified survived at least 1 year after macro CK was found in their serum. Age and gender did not differ significantlybetween the two groups. The serum total CK was significantly higher (P <0.0005), and an increased CK-MB proportion (>0.05 of total CK) was also significantly more common (P <0.0005) in patients with macro CK type 1 than in those with type 2. On average, macro CK type 2 accounted for -25% and macro CK type 1 for -10% of the serum total CK activity. Patients with macro CK type 1 most often had myositis, whereas those with macro CK type 2 most commonly had a malignancy. We conclude that the presence of macro CK isoenzymes has a low prognostic value for impending death, but may support the diagnosis of an autoimmune process (type 1) or malignant cell proliferation (type 2). 
Macro CK type 2 is believed to represent oligomeric mitochondrial CK (10, 11, 21-29).
Electrophoretically, this is the so-called cathodic macro CK, migrating cathodal to CK-MM (Fig. 1) . The extreme cathodal mobility (21, 26) , the unusually high activation energy (11) , the enzyme kinetics (7), and the stability upon heating (8) all support a mitochondrial origin for macro CK type 2.
Unlike the three common CK isoenzymes, the clinical significance of the macro CK forms is poorly understood. Thus, in 136 patients identified as having macro CK, we analyzed the relation between the macro CK isoenzymes types 1 and 2 and other laboratory and clinical data.
Materials and Methods
Patients. The study population consistedof 8322 inpatients and outpatients for whom CK isoenzyme analysis was ordered at the W. G. Magnuson Clinical Center of the National Institutes of Health over a 54-month period. Patients with macro CK in their serum were followed for 1 to 70 months regarding mortality. Serum total CK Total serum CK was determined afterN-acetylcysteine activation by using the hexokinase and glucose-6-phosphate dehydrogenase reaction coupled to the production of ATP 
Resufts

General characteristics
of patients with macro CK Among the 8322 patients, we identified 136 patients who expressed macro CK isoenzyme in their serum (Table 1). Patients with macro CK type 1 and type 2 were comparable for age distribution. Although the difference was not statistically significant, macro CK type 1 occurred more often in women than men, whereas macro CK type 2 occurredequally among both sexes (Table 1) . Most patients (73%) were ambulatory at the time of blood sampling ( Table 1 ). The mortality rate was low in both groups and, on the basis of our findings for the first 68 patients, almost 90% survived at least 1 year after we identified macro CK in their serum (Table 1) .
Total CK and the fraction and activity of macro CK Mean total CK activity was 10-fold higher in patients with macro CK type 1 than in those with type 2 (Table 
2). This difference was further illustrated by the per-
centage of patients whose serum total CK was <100 UIL, a decision level commonly used by thboratories for rejecting specimens for CK electrophoresis, or >500 UIL, an unequivocally above-normal activity (Fig. 2) . Of the patients macro CK type 1,64% had total CK >500 U/L, whereas 72% of the patients with macro CK type 2 had total CK activity <100 U/L. These differences were also apparent in relationto the reference interval; only 19% of the patients with macro CK type 1, vs 73% of patients with type 2, had serum total CK within the gender-specific reference intervals. The macro CK fraction was more than twice as great (P <0.001) in patients with type 2 as in those with type 1; however, because of great differences in totalCK, the mean activity of macro CK was about sevenfold greater (P <0.04) in patients with type 1 than in those with type 2 (Table 2) . CK-BB and CK-MB in patients with macro CK Most patients (32 of 36, or 89%) with macro CK type 1, but only about half (55%) of the 100 patients macro CK type 2 had detectable serum CK-BB and (or) CK-MB. Detectable CK-BB was about 10-fold more common in patients macro CK type 2 than type 1 (Table 3) . Increased CK-MB fraction (>0.05) occurred about fivefold more often in patients with macro CK type 1 than in those with type 2, statistically a highly significant difference (P <0.0005) (Fig. 2) . We also found discernible CK-MB significantly more frequently (P <0.0005) in patients with macro CK type 1 than in those with type 2 (Table 3 ). More than 80% of the patients with macro CK type 1, vs only 25% of those with type 2, had detectable CK-MB (Table 3 ). When present, CK-MB accounted for about the same fraction of total CK in both patients macro CK type 1 and type 2 but the activity of total CK was significantly higher (P <0.003) in patients with macro CK type 1 than in those with type 2 (Table 3) .
Clinical diagnoses of patients with macro CK A diagnosis of heart or skeletal muscle disease was significantly (P <0.0005) more common in patients with macro CK type 1 than in those with type 2 (Fig. 2) . Further analysis showed highly significant (P <0.0005) differences between the two groups of patients in two diagnostic categories: myositis and malignancy (Fig. 3) . My- and drug-induced myositis, was diagnosed in >50% of the patients with macro CK type 1 but in only 4% of those with macro CK type 2. In turn, malignancy was more than threefold more common in patients with macro CK type 2 than in those with type 1 (Fig. 3) . In the group with macro CK type 1, 77% (24 of 31) of the patients with detectable CK-MB had heart or skeletal muscle disease, whereas in the group with macro CK type 2, 33% (8 of 24) of the patients with detectableCK-MB had heart or skeletal muscle disease(and only 2 had myositis). In the single patient with macro CK type 1 and detectable CK-BB, atrial septal defect and hypothyroidism were the clinical diagnoses.
In the group with macro CK type 2, 68% (21 of 31) of the patients with detectable CK-BB had a diagnosisof cancer,whereas 8 of the remaining 10 cases (i.e., 26% of the patients with detectableCK-BB) had myositis or heart disease.
The combination of both serum CK-MB and CK-BB was present only in patients with macro CK type 2 (16%, 16 of 100). Ten patients had various malignancies, three had heart disease,two had myositis, and one had an infectious disease.
Inhibitory studies on macro CK-2 with antibodies to CK-MM. Inhibitory studies with antibodies to human CK-MM showed dose-dependent (and ultimately complete) elimination of CK-MM but no effect on the cathodal-migrating macro CK band-indicating antigenic differences. 
Discussion
Despite numerous reports on macro CK isoenzymes (1-29) , the clinical relevance of the isoenzymes remains unclear for at least two reasons. First, the relatively low prevalence of macro CK in both the general and hospitalizedpopulation hampers the collection of a large number of cases for analysis. Second, preselection of the patients by age, sex, and disease characteristics and the method(s) used to detect macro CK all affect disease associations, prevalence estimates, outcome analyses, and so forth. In this study, we analyzed a comparatively large number of patients with macro CK types 1 and 2.
Early studies disclosed wide variations in the prevalence of macro CK type 1 among different disease categories;no association with a specific disease was evident (2, 3, 28) . In the largest study, based on the use of counterimmunoelectrophoresis, the incidence of CKimmunoglobulin complexes increased with age (19). Further, the incidence of CK-IgG but not CK-IgA complexes showed association with autoimmune diseases, particularly ulcerative colitis (19). In another study, macro CK type 1 was associatedwith complications of cardiovascular disease, gastrointestinal disease, autoimmune disorders, life-threatening conditions such as trauma, and poor outcome (defined as increased death rate within 2 years) in adult patients (20) . Macro CK type 1 has been occasionally detected in children (15) and even in apparently healthy individuals (12). Our findings are at variance with these previous reports. Most of our patients had heart or skeletal muscle disease,especially myositis. Our observation of commonly increasedserum total CK and CK-MB is consistent with these disease associations and with a proposed autoimmune etiology for macro CK type 1 (2-6, 9, 13,  20) . That we found more female patients with macro CK type 1 than type 2 also is in accord with an autoimmune etiology (commonly  myositis) and previous data (20,27, 28). However, analyzing survival rates at 1 instead of 2 years afterthe diagnosis of macro CK type 1 (20), we failedto confirm that the presence of macro CK type 1 is a poor prognostic sign.
The prevalence of macro CK type 1 has been reported to range from 0.54% to 2.3%, but several studies suggest a prevalence of 0.9%-1.2% (3). Using the technique of counterimmunoelectrophoresis, Tozawa (19) found CKlinked immunoglobulins in 0.61% of >42 000 randomly selected patients and in 0.23% of 10000 blood donors. In another large study (20), the prevalence of macro CK type 1 was 0.54% among patients for whom a CK isoenzyme analysis was ordered (n = 1304, 794 men and 510 women, ages 20-69 years), whereas no case of macro CK type 1 was found among age-and sex-matched healthy blood donors (n = 1304). In addition, the same investigators reportedan overall prevalence of 0.61% (49 cases of macro CK type 1 among 8800 patients selected for CK isoenzyme analysis) in their laboratory over a 40-month period (20). Lott (14) reported a 0.5% occurrence of macro CK type 1 among 4259 patients for whom both total and CK isoenzyme analyses were performed. We found a comparable prevalence rate (0.43%) for macro CK type 1 in our study group of 8322 hospitalized or ambulatory patients for whom CK isoenzyme electrophoresis was requested over a 54-month period. However, we could have missed some casesof macroCK type 1 if the electrophoretic migration of their complex approximated that of CK-MB or CK-MM (1, 19) . In previous studies, macro CK type 2 (mitochondrial CK) has been detected predominantly in severely ill patients of all ages (2, 3, 15, 21-29) .
In adults, macro CK type 2 was mainly seen in association with malignant tumors or severe liver damage (e.g., cirrhosis) (2, 3, 15, [21] [22] [23] [24] [25] [26] [27] [28] [29] , whereas in children it was associated with myocardial disease (15). No preponderance by sex was noted in these studies (3, 28)-a finding confirmed by our data. Although the presence of macro CK type 2 was initially thought to indicate impending death in general (32) or only in patients with malignancy (33), it is now believed to be a sign of serious illness with high mortality but not inevitably a sign of impending death (28). Our findings confirm this latter observation.
Although serious illnesses (e.g., cancer and cardiovascular and infectiousdiseases)were the leading diagnoses in our study group, survivaldata showed that the presence of macro CK type 2 does not necessarilyindicateimpending death. The failure of antibodies to CK-MM to block the activity of macro CK type 2is also consistent with the proposed mitochondrial origin of this macro CK type (1) (2) (3) (21) (22) (23) (24) (25) (26) (27) (28) (29) .
Because of the cathodal mobility of AK in our separation system, we cannot, however, completely rule out the possibility that some of our cases of macro 
34-40).
Consequently, either an inappropriate diagnosis of myocardial injury may be made and unnecessary treatment initiated, or, conversely, a false-negative laboratory diagnosis may delay the recognition and treatment of a real myocardial infarction.
In summary, there are characteristic differences between patients with macro CK type 1 and type 2 (Table  4) . From our data, we condude that the presenceof these isoenzymes has low prognostic value for impending death but may support the diagnosisof an autoimmune process (CK-immunoglobulin complex or macroCK type 1) or of malignant cell proliferation (mitochondrialor macroCK type 2). The recognition and understanding of macro CK isoenzymes are requiredfor correct interpretation of CK isoenzyme results in laboratory and clinical medicine. 
